Browsing by Author "Tamas, Maria-Magdalena (36817118000)"
Now showing 1 - 1 of 1
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication "To be or not to be," ten years after: Evidence for mixed connective tissue disease as a distinct entity(2012) ;Cappelli, Susanna (36096543700) ;Bellando Randone, Silvia (35218795900) ;Martinović, Dušanka (16417426000) ;Tamas, Maria-Magdalena (36817118000) ;Pasalić, Katarina (51864514400) ;Allanore, Yannick (7003519327) ;Mosca, Marta (7006720974) ;Talarico, Rosaria (24330409200) ;Opris, Daniela (15756184400) ;Kiss, Csaba G. (18340304000) ;Tausche, Anne-Kathrin (55915616000) ;Cardarelli, Silvia (57226555478) ;Riccieri, Valeria (7003568453) ;Koneva, Olga (6508032421) ;Cuomo, Giovanna (58021681500) ;Becker, Mike Oliver (57199798838) ;Sulli, Alberto (7003533074) ;Guiducci, Serena (6701771669) ;Radić, Mislav (56277745800) ;Bombardieri, Stefano (7006270830) ;Aringer, Martin (7003332848) ;Cozzi, Franco (35271801400) ;Valesini, Guido (7005133584) ;Ananyeva, Lidia (6603356433) ;Valentini, Gabriele (7102929864) ;Riemekasten, Gabriela (57203073213) ;Cutolo, Maurizio (7103329735) ;Ionescu, Ruxandra (36196636800) ;Czirják, László (7004435091) ;Damjanov, Nemanja (8503557800) ;Rednic, Simona (16417734900)Matucci Cerinic, Marco (7005642558)Objectives: To determine if mixed connective tissue disease (MCTD) can be considered an independent clinical entity, to compare 3 different classification criteria for MCTD (Kasukawa, Alarcón-Segovia, and Sharp), and to define predictors (clinical features and autoantibodies) of potential evolution toward other connective tissue diseases (CTDs). Methods: One hundred sixty-one MCTD patients were evaluated retrospectively at the diagnosis and in 2008. They were classified, at the diagnosis, according to the 3 classification criteria of MCTD (Sharp, Alarcón-Segovia, and Kasukawa) and reclassified in 2008 according to their evolution. Statistical analyses were performed to find out predictors (clinical features and autoantibodies) of evolution into other CTDs. Results: After a mean of 7.9 years of disease, 57.9% of patients still satisfied MCTD classification criteria of Kasukawa; 17.3% evolved into systemic sclerosis, 9.1% into systemic lupus erythematosus, 2.5% into rheumatoid arthritis, 11.5% was reclassified as affected by undifferentiated connective tissue disease, and 1.7% as suffering from overlap syndrome. Kasukawa's criteria were more sensitive (75%) in comparison to those of Alarcón-Segovia (73%) and Sharp (42%). The presence of anti-DNA antibodies (P = 0.012) was associated with evolution into systemic lupus erythematosus; hypomotility or dilation of esophagus (P < 0.001); and sclerodactyly (P = 0.034) with evolution into systemic sclerosis. Conclusions: MCTD is a distinct clinical entity but it is evident that a subgroup of patients may evolve into another CTD during disease progression. Initial clinical features and autoantibodies can be useful to predict disease evolution. © 2012 Elsevier Inc.
